A larger company in your industry offers to become a strategic investor in your business. The valuation is attractive, and its name on your shareholder list tells customers, partners, and future investors that someone serious has looked closely at the company. That combination is hard to turn down, and often it should not be turned down.
The capital is real, and so is the endorsement. But a strategic investor’s interest is tied to its own business, and the rights it asks for usually reflect that. Those rights can shape the company’s options for years.
The valuation is the visible price of a strategic investment. The less visible price is how much of the company’s future flexibility comes with it.
How Is a Strategic Investor Different From a Financial Investor?
A strategic investor is usually buying two things: a financial return and a position relative to the company’s future. A financial investor, such as a venture capital or private equity fund, invests mainly for financial return and wants the company eventually sold or taken public at the best available price. A strategic investor is an operating company, or its venture arm, that also invests for business reasons: access to a technology, a market, a supply relationship, or a future acquisition.
Those business reasons are often what make a strategic investor valuable. It can bring industry knowledge, customer relationships, and credibility that a fund cannot. They are also what make the terms worth a closer look. Corporate money is now a major part of private markets: in 2025, about one in five venture rounds worldwide included a corporate investor, according to Global Venturing.
What Does a Strategic Investor’s Money Really Buy?
Beyond shares, a strategic investment can give the investor influence in three areas that matter for the company’s future: who it partners with, who sees its plans, and who can buy it. Exclusivity or first-negotiation rights can keep other partners away. Board and observer seats can give a potential competitor or acquirer a view into sensitive discussions. A right of first refusal on a sale, which lets the investor match any outside offer, can discourage other buyers from bidding at all.
A right of first refusal costs nothing on paper. In practice, it can decide who is willing to bid.
None of these terms is unusual, and none is automatically a problem. Their effect depends on scope, duration, and how they fit the company’s plans, which makes them a strategic judgment as much as a legal one.
A Clear Illustration: Pharma Investment in Biotech
Life sciences shows both sides clearly. Pharmaceutical companies’ venture arms have become some of the most active investors in private biotech, and a Silicon Valley Bank report published in July 2025 found that at least 70 percent of biopharma IPOs since 2022 included a corporate venture investor. For a drug developer, a pharma investor can bring validation and a potential future partner. But if that investor holds rights over the lead program, other partners may treat the asset as spoken for, just when competing interest matters most.
When Should a Company Evaluate a Strategic Investment?
Before the term sheet. Once the key terms are summarized on paper, they frame the rest of the negotiation, and the company’s room to shape what the investor receives narrows quickly.
A strategic investment is a partnership decision as much as a financing decision. Companies that treat it that way from the start, weighing what the money really buys and not only what it is worth, keep more of the options they will need later.
Common Questions
What is the difference between a strategic investor and a financial investor?
A financial investor, such as a venture capital or private equity fund, invests mainly for financial return. A strategic investor is an operating company, or its venture arm, that also invests for business reasons, such as access to a technology, a market, or a future acquisition.
Is a right of first refusal for a strategic investor a problem?
It can be. Because the investor can match any offer, other buyers may be less willing to bid, which can reduce competition when the company is sold. Whether it is acceptable depends on its scope and the company’s plans.
When should a company get advice on a strategic investment?
Ideally before the term sheet, while the company still has room to shape what the investor receives.
David Y.K. Kim is the Principal Attorney and Strategic Advisor of Crossbridge Law Group, which offers senior legal counsel and strategic business advice in one firm. The firm advises companies, founders and business owners, and investors on outside general counsel, business transactions, and cross-border matters, and through its Strategic Advisory practice, on partnering and licensing, financing strategy, and other major business decisions. The firm is based in Irvine, California and serves clients across Southern California. A graduate of Harvard Law School, he previously practiced at A&O Shearman, served as senior in-house counsel at Merrill Lynch, was an investment banker at J.P. Morgan, and also worked as a business consultant. His work includes advising companies on strategic partnerships and investments involving larger industry counterparties.
